Literature DB >> 2038423

Theophylline and status epilepticus in children.

D W Dunn1, H U Parekh.   

Abstract

We studied the role of theophylline on outcome of status epilepticus (SE) in children. During a two-year-period, 16 of 114 episodes of SE occurred in children receiving theophylline. At the onset of SE, theophylline blood levels were elevated in 8 episodes, and were therapeutic or subtherapeutic in 8 episodes. In the 8 episodes of SE with elevated theophylline levels, one child died and three suffered permanent new neurologic deficits. In the 8 episodes of SE with normal or low theophylline levels, only one child had a transient deficit. The occurrence of death or disability in 4 of 8 episodes of SE with elevated theophylline was considerably higher than the 23% incidence of death or persistent CNS deficit in the overall series of 114 episodes of SE. We conclude that theophylline, at toxic levels, is a significant factor in increased morbidity. We suspect that the hypoxia from the respiratory disorder for which theophylline was used, and the reduced cerebral blood flow known to occur with theophylline led to a failure to compensate for the increased cerebral metabolic rate of SE, thus increasing the risk of a poor outcome.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2038423     DOI: 10.1055/s-2008-1071410

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  3 in total

Review 1.  Theophylline. Current thoughts on the risks and benefits of its use in asthma.

Authors:  S S Nasser; P J Rees
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

2.  Theophylline-associated status epilepticus in an infant: pharmacokinetics and the risk of suppository use.

Authors:  Zenichiro Kato; Atsushi Yamagishi; Mitsuhiro Nakamura; Naomi Kondo
Journal:  World J Pediatr       Date:  2009-11-13       Impact factor: 2.764

3.  Association of epilepsy and asthma: a population-based retrospective cohort study.

Authors:  Kuo-Liang Chiang; Jen-Yu Lee; Fang-Chuan Kuo; Chin-Yin Huang
Journal:  PeerJ       Date:  2018-05-18       Impact factor: 2.984

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.